Equities

Kyorin Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,473.00
  • Today's Change5.00 / 0.34%
  • Shares traded80.10k
  • 1 Year change-18.03%
  • Beta0.1527
Data delayed at least 20 minutes, as of Nov 13 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.

  • Revenue in JPY (TTM)119.73bn
  • Net income in JPY4.82bn
  • Incorporated1958
  • Employees2.04k
  • Location
    Kyorin Pharmaceutical Co Ltd8F-10F, Nikkei Bldg., 1-3-7, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 363749700
  • Fax+81 335254780
  • Websitehttps://www.kyorin-pharm.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cuorips Inc19.39m-657.94m51.14bn59.00--8.74--2,637.67-88.11-88.112.60729.160.00321.1510.60328,610.20-10.89---11.14--44.66---3,394.40--35.37--0.00---39.65---39.84------
ASKA Pharmaceutical Holdings Co Ltd63.57bn5.98bn64.89bn762.0010.060.93817.791.02210.94210.942,243.732,263.170.70561.643.8683,419,940.006.634.638.445.8749.3846.949.406.761.71--0.106414.863.946.1278.0334.04-37.8923.36
Katakura Industries Co., Ltd.38.12bn2.89bn68.95bn1.04k22.270.830715.891.8187.9287.921,158.052,357.160.27251.995.3736,650,960.002.172.352.793.3438.6237.757.978.322.56--0.102618.8116.62-2.048.0918.87-7.4610.76
JCR Pharmaceuticals Co Ltd35.26bn-437.00m85.07bn934.00--1.4527.222.41-3.49-3.49281.91451.840.3380.47912.1537,747,320.00-0.38648.66-0.568113.4671.4474.51-1.1418.240.9827-0.81840.332530.6024.8313.1146.008.1918.5421.67
Kyorin Pharmaceutical Co Ltd119.73bn4.82bn94.84bn2.04k17.510.648610.260.792183.8383.832,084.192,263.350.67451.213.1858,635,650.002.713.053.363.7942.8747.114.024.761.74--0.159367.745.531.0212.68-4.987.41-7.06
Nxera Pharma Co Ltd29.28bn-3.71bn108.06bn350.00--1.59428.823.69-41.70-41.70332.11753.720.1942.576.6183,642,860.00-2.46-0.6588-2.76-0.703675.2789.83-12.68-4.463.90-6.020.5060---18.00---1,982.98------
Zeria Pharmaceutical Co Ltd78.88bn9.03bn118.99bn1.78k10.941.217.091.51204.82204.821,789.401,858.720.54181.503.7144,387,400.006.203.899.826.2873.2271.9311.447.570.8393--0.350835.0910.744.1424.7817.4920.775.29
Mochida Pharmaceutical Co Ltd104.51bn4.53bn123.65bn1.52k25.830.906116.641.18127.75127.752,945.163,641.810.66391.803.4268,662,940.002.884.373.415.3149.6152.474.346.713.50--0.0045.16-0.3641-1.26-31.61-11.6310.91-1.21
Torii Pharmaceutical Co Ltd58.84bn5.28bn126.86bn583.0023.471.0322.272.16187.71187.712,093.334,271.840.44112.742.30100,924,500.003.966.524.397.3544.4649.558.9717.985.19--0.0024.1711.74-2.674.4428.76-20.3820.11
Data as of Nov 13 2024. Currency figures normalised to Kyorin Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

19.77%Per cent of shares held by top holders
HolderShares% Held
Kopernik Global Investors LLCas of 15 Jul 20244.68m7.24%
Amundi Japan Ltd.as of 07 Nov 20241.83m2.84%
Nomura Asset Management Co., Ltd.as of 03 Oct 20241.37m2.11%
The Vanguard Group, Inc.as of 02 Oct 20241.35m2.10%
BlackRock Fund Advisorsas of 03 Oct 2024796.30k1.23%
Dimensional Fund Advisors LPas of 03 Oct 2024688.01k1.07%
Nikko Asset Management Co., Ltd.as of 04 Oct 2024635.70k0.98%
Daiwa Asset Management Co. Ltd.as of 30 Sep 2024614.80k0.95%
Janus Henderson Investors (Singapore) Ltd.as of 30 Sep 2024468.20k0.73%
Norges Bank Investment Managementas of 30 Jun 2024337.77k0.52%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.